BIVI — BioVie Income Statement
0.000.00%
HealthcareSpeculativeSmall CapMomentum Trap
- $163.04m
- $154.53m
Annual income statement for BioVie, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2018 June 30th | 2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2.37 | 2.5 | 2.69 | 138 | 27.3 |
Operating Profit | -2.37 | -2.5 | -2.69 | -138 | -27.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.41 | -2.44 | -16.7 | -130 | -26.1 |
Net Income After Taxes | -2.41 | -2.44 | -16.7 | -130 | -26.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.41 | -2.44 | -16.7 | -130 | -26.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.43 | -2.49 | -33.8 | -184 | -26.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.18 | -0.982 | -6.85 | -14.8 | -1.06 |